Cerebral palsy
Drug research and approvals for cerebral palsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 341 studies of cerebral palsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 3 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 341
- Trials authorized in Canada: 2
- FDA orphan approvals: 3
- EU medicines: 0
- Spinal Cord Stimulation Combined With Brain-Computer Interface Rehabilitation to Improve Motor Function After StrokeNCT07941908 · Not reported · Qingdao Central Hospital · starts Oct 21, 2026
- Effect of Core Stability Training Versus Balance Training on Postural Control, Balance and Functional Outcome in…NCT07942896 · Not applicable · Ibadat International University, Islamabad · starts Nov 10, 2026
- Development and Validation of an AI-Driven Motor Skill Assessment System for ChildrenNCT07940153 · Not reported · Chang Gung Memorial Hospital · starts Sep 1, 2026
- An Early Feasibility Study of a Robotically Implanted Brain-Computer Interface for Neural Control of External Devices…NCT07929792 · Not applicable · Neuralink Corp · starts Nov 1, 2026
- Effects of Functional Electrical Stimulation Combined With Task-Oriented Training on Lower Limb Function, Balance, and…NCT07924813 · Not applicable · Lahore University of Biological and Applied Sciences · starts Oct 12, 2026
- Sensory Integration Therapy vs Conventional Physical Therapy in Children With Mixed Cerebral PalsyNCT07921069 · Not applicable · Riphah International University · starts Oct 21, 2026
- Comparison of Vestibular Stimulation and Core Stability Training on Sitting Balance in Hypotonic CPNCT07921186 · Not applicable · Riphah International University · starts Jul 1, 2026
- Telerehabilitation Compared With Clinic-Based Physiotherapy in Children With Spastic Cerebral PalsyNCT07921147 · Not applicable · Riphah International University · starts Oct 21, 2026
- Additional Effects on tDCS With AOT on Lower Limb Functions on Children With Diplegic CPNCT07921095 · Not applicable · Riphah International University · starts Jul 1, 2026
Approved 5
- BaclofenGABA-B receptor agonist
- DiazepamGABA-A receptor; anion channel positive allosteric modulator
- DantroleneRyanodine receptor 1 antagonist
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- CyclobenzaprineSerotonin 2a (5-HT2a) receptor antagonist
Phase 3 4
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- TetrabenazineSynaptic vesicular amine transporter inhibitor
- IbuprofenCyclooxygenase inhibitor
- Nabiximols
Phase 2 5
- Epoetin betaErythropoietin receptor agonist
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- Autologous cord blood
Phase 1 or earlier 2
- RimabotulinumtoxinbVesicle-associated membrane protein 2 inhibitor
- DalfampridineVoltage-gated potassium channel blocker
How its trials ended
1,545 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 123 whose ending is known, 46% met their primary endpoint, 5% missed it and 49% stopped early.
- Completed, result not reported82353%
- Ongoing36323%
- Status unknown23615%
- Met its primary endpoint574%
- Stopped: other or unclear372%
- Stopped: enrollment or feasibility111%
- Missed its primary endpoint6<1%
- Stopped: lack of efficacy6<1%
- Stopped: funding4<1%
- Stopped: sponsor or business decision2<1%
| Dec 11, 2018 | A randomized, double-blind, placebo-controlled study of TEV-50717 (deutetrabenazine) for the treatment of dyskinesia in cerebral palsy in children and…Deutetrabenazine (TEV-50717) | Teva Pharmaceutical Industries | Closed |
| Nov 28, 2017 | Metformin for motor and cognitive improvement in children with cerebral palsy: a feasibility studyMetformin | Bloorview Research Institute | Closed |
| Jun 20, 2019 | BotoxBOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age. | Allergan, Inc. | Approved |
| Jul 29, 2016 | DysportTreatment of lower limb spasticity in pediatric patients 2 years of age and older | Ipsen Biopharmaceuticals, Inc. | Approved |
| Jul 28, 2010 | CuvposaTo reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy) | Shionogi, Inc. | Approved |
| Jul 24, 2012 | Autologous umbilical cord bloodTreatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury | Duke University | Designated |
| Sep 26, 1994 | BaclofenTreatment of spasticity associated with cerebral palsy. | Medtronic, Inc. | Designated |
| Jan 30, 1992 | L-baclofenTreatment of intractable spasticity in children with cerebral palsy. | Osmotica Pharmaceutical Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA